Hemostemix Short Ratio vs. EBITDA

HEM Stock  CAD 0.06  0.01  14.29%   
Based on the key profitability measurements obtained from Hemostemix's financial statements, Hemostemix may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Hemostemix's ability to earn profits and add value for shareholders. At this time, Hemostemix's ROIC is fairly stable compared to the past year. Days Payables Outstanding is likely to climb to about 4.9 M in 2024, despite the fact that Book Value Per Share is likely to grow to (0.08).
For Hemostemix profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hemostemix to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hemostemix utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hemostemix's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hemostemix over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Hemostemix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hemostemix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hemostemix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Hemostemix EBITDA vs. Short Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Hemostemix's current stock value. Our valuation model uses many indicators to compare Hemostemix value to that of its competitors to determine the firm's financial worth.
Hemostemix is rated # 3 in short ratio category among its peers. It is rated # 4 in ebitda category among its peers . Hemostemix reported EBITDA of (2.16 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemostemix's earnings, one of the primary drivers of an investment's value.

Hemostemix EBITDA vs. Short Ratio

Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Hemostemix

Short Ratio

 = 

Short Interest

Average Trading Volume

 = 
0.17 X
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Hemostemix

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(2.16 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Hemostemix EBITDA Comparison

Hemostemix is currently under evaluation in ebitda category among its peers.

Hemostemix Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Hemostemix, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hemostemix will eventually generate negative long term returns. The profitability progress is the general direction of Hemostemix's change in net profit over the period of time. It can combine multiple indicators of Hemostemix, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.5 M1.5 M
Operating Income-2.2 M-2.3 M
Net Loss-2.5 M-2.6 M
Income Before Tax-2.5 M-2.6 M
Total Other Income Expense Net-345.1 K-327.9 K
Net Loss-4.7 M-4.9 M
Net Loss-2.5 M-2.6 M
Income Tax Expense(3.00)(2.85)
Net Interest Income-556.1 K-528.3 K
Interest Income84 K88.2 K
Change To Netincome964.1 KM
Net Loss(0.03)(0.03)
Income Quality 0.57  0.81 
Net Income Per E B T 0.99  0.82 

Hemostemix Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Hemostemix. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hemostemix position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hemostemix's important profitability drivers and their relationship over time.

Use Hemostemix in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hemostemix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hemostemix will appreciate offsetting losses from the drop in the long position's value.

Hemostemix Pair Trading

Hemostemix Pair Trading Analysis

The ability to find closely correlated positions to Hemostemix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hemostemix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hemostemix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hemostemix to buy it.
The correlation of Hemostemix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hemostemix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hemostemix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hemostemix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Hemostemix position

In addition to having Hemostemix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ISP Thematic Idea Now

ISP
ISP Theme
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Hemostemix Stock Analysis

When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.